Saracatinib
Saracatinib
Saracatinib (pronounced sah-rah-KAH-ti-nib) is a small molecule inhibitor that targets Src family kinases and ABL kinases. It is primarily used in the research and treatment of various cancer types.
Etymology
The name "Saracatinib" is derived from the pharmaceutical company that developed it, AstraZeneca, and the class of drugs it belongs to, known as tyrosine kinase inhibitors. The "-tinib" suffix is common among this class of drugs.
Usage
Saracatinib is used in the treatment of various types of cancer, including breast cancer, lung cancer, and colorectal cancer. It works by inhibiting the activity of certain proteins that are involved in the growth and spread of cancer cells.
Related Terms
- Tyrosine kinase inhibitor: A type of drug that blocks the action of enzymes known as tyrosine kinases, which can promote the growth of cancer cells.
- Src family kinases: A family of non-receptor tyrosine kinases that play key roles in cell growth, division, migration, and survival.
- ABL kinases: A group of proteins that are involved in regulating the cell cycle and are often overactive in cancer cells.
See Also
External links
- Medical encyclopedia article on Saracatinib
- Wikipedia's article - Saracatinib
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski